by Company Biotechnology ContraFect

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biological therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. The company focuses on phage biology to develop and commercialize novel, first-in-class biologic therapies, known as direct lytic agents (DLAs), which include lysins and amurin peptides, as new medical modalities to treat life-threatening infections, including those caused by drug-resistant pathogens.

Lysin bacteriophage-based product pipeline:

  • Exebacase – target: Staphylococcus aureus
  • CF-296 – target: Staphylococcus aureus
  • CF-370 – target: Pseudomonas aeruginosa
  • GN (Gram-negative) Lysins – target: Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae and Acinetobacter baumannii
  • GN (Gram-positive) Lysins – target: Streptococcus pneumoniae, Enterococcus faecalis Group B Streptococcus and Bacillus anthracis

Amurin bacteriophage-based product pipeline:

  • Amurins – Broad-spectrum; Gram-negative ESKAPE pathogens

This website uses cookies. Accept Read More